Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever

Scandinavian Journal of Infectious Diseases

Volumn 28, Issue 3, 1996, Pages 297-303

  Engervall, Per ^a   Günther, Göran ^b   Ljungman, Per ^a   Lönnqvist, Berit ^a   Hast, Robert ^b   Stiernstedt, Göran ^a   Kalin, Mats ^a   Ringertz, Signe ^a   Bjökholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; COTRIMOXAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

EID: 0029770649     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549609027177     Document Type: Article

References (28)

1. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Mayers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381-396, 1990.
2. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284: 1061-1065, 1971.
3. Pizzo P. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 328: 1323-1332, 1993.
4. Pizzo P, Hathorn J, Heimenz J, Browne M, Commers J, Cotton D, Gress J, Long D, Marshall D, McKnight J, Rubin M, Skeleton J, Thaler M, Wesley R. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552-558, 1986.
5. Sanders JW, Powe NR, Moor RD. Ceftazidime monotherapy for empiric treatment of neutropenic patients: a metaanalysis. J Infect Dis 164: 907-916, 1991.
6. Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Johi JH, Keating MJ, Holms FA, Cabanillas FF, Eking L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152: 283-291, 1992.
7. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P. Cefazidime compared with piperacillin and tobramycin for empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 120: 834-844, 1994.
8. Engervall P, Stiernstedt G, Günther G, Björkholm M. Trimethoprim - sulfamethoxazole plus amikacin as first empirical therapy and imipenem/cilastatin as secondary therapy in febrile neutropenic patients with hematological disorders. J Chemotherapy 4: 99-106, 1992.
9. Young LS, Hindler J. Use of trimethoprim-sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients. Rev Infect Dis 9: 177-181, 1987.
10. Stuart R, Braine H, Lietman P, Saral R, Fuller D. Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients: a prospective, randomized, double-blind study. Am J Med 86: 876-885, 1980.
11. Bodey GP, Grose AWE, Keating MJ. Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 4: 579-585, 1982.
12. Braine HG, Stuart RK, Saral R, Lietman PS. Parenteral trimethoprim sulfamethoxazole and carbenicillin as empiric therapy for neutropenic patients with cancer. Rev Infect Dis 4: 586-592, 1982.
13. Günther G, Björklind A, Engervall P, Björkholm M, Stiernstedt G. Septicemia in patients with hematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile. Scand J Infect Dis 23: 589-598, 1991.
14. Samuelson J, Lönnqvist B, Palmblad J, Grimfors G, Järnmark M, Lerner R, Ljungman P, Nyström-Rosander C, Öberg G. Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Scand J Infect Dis 24: 89-96, 1992.
15. Axdorph U, Laurell G, Björkholm M. Monitoring of hearing during treatment of leukemia with special reference to the use of amikacin. J Intern Med 233: 401-407, 1993.
16. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161: 397-401, 1990.
17. The EORTC International Antimicrobial Therapy Project Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteraemia in cancer patients with granulocytopenia. N Engl J Med 317: 1692-1698, 1987.
18. De Jongh CA, Joshi JH, Thompson BW, Newman KA, Finley RS, Moody MR, Salatore PC, Tenney JH, Drusano GL, Schimpff SC. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 80: 101-111, 1986.
19. Menichetti F, Del Favero A. The role of Gram-positive therapy in the neutropenic patient. J Antimicrob Chemother 27: 51-60, 1991.
20. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients. J Infect Dis 163: 951-958, 1991.
21. Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone J-D, Rand KH, Giliom M, Shands Jr. JW, Kramer BS. Vancomycin is not essential component of the initial empirical treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36: 1062-1067, 1992.
22. De Jongh CA, Johshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC. Antibiotic synergism and response in gram-negative bacteraemia in granulocytopenic cancer patients. Am J Med 80: 96-111, 1986.
23. Golde DW, Bersch N, Quan SC. Trimethoprim and sulfamethoxazole inhibition of haematopoiesis in vitro. Br J Haematol 40: 363-367, 1978.
24. Kinsey SE, Machin SJ, Goldstone AH. Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. J Hosp Infect 15: 49-53, 1990.
25. Viscoli C, Moroni C, Boni L, Bruzzi P, Comelli A, Dini G, Fabbri A, Secondo V, Terragna A. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 13: 397-404, 1991.
26. Goldstein FW, Coutrot A, Sieffer A, Acar JF. Percentage and distributions of teicoplanin- and vancomycin-resistant stains among coagulase-negative staphylococci. Antimicrobial Agents Chemother 34: 899-900, 1990.
27. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316: 927-931, 1987.
28. Fredlund H, Björeman M, Kjellander J, Sjöberg L, Bjorne L, Öhlin A-L. A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital. Scand J Infect Dis 22: 381-391, 1990.